Remission of polycystic ovary syndrome based on the recovery of ovarian morphology identified by three-dimensional ultrasonography: a retrospective study
Abstract
Background: Polycystic ovary syndrome (PCOS) is a prevalent chronic disease, yet the concept of PCOS remission and its predictors remain poorly understood.
Objectives: This study investigated PCOS remission rates via three-dimensional (3D) ultrasonography assessment of ovarian morphological normalization.
Methods: This retrospective study included 1379 reproductive-aged PCOS women from Shanghai Tenth People's Hospital (Aug. 2019-Dec. 2025). After medication initiation, anthropometric, biochemical, and reproductive data (both baseline and post-treatment) were collected quarterly, while 3D ultrasonography was used to evaluate polycystic morphology during follow-up.
Results: Among the 468 eligible participants, 55 (11.75%) achieved clinical remission of PCOS, defined as restoration of regular menses, normalization of serum testosterone levels, and recovery of normal ovarian morphology. The mean time to remission was 12.76 ± 11.77 months. Patients in the clinical remission group were frequently prescribed insulin-sensitizing and weight-loss agents, including metformin, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose linked transporter 2 inhibitors (SGLT-2is), and thiazolidinediones (TZDs). Following treatment, the remission group exhibited significant increases in menstrual cycle frequency and estradiol (E2), together with significant reductions in body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), alanine aminotransferase (ALT),…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 468 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.